- Home
- RUBI vs DCOY Comparison
RUBI vs DCOY Comparison
Compare RUBI & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUBI | DCOY |
|---|---|---|
| Founded | 2022 | N/A |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.2M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RUBI | DCOY |
|---|---|---|
| Price | $1.13 | $2.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 261.3K | ★ 4.0M |
| Earning Date | 05-06-2020 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.53 |
| 52 Week High | $6.69 | $13.51 |
Technical Indicators
Market Signals| Indicator | RUBI | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 27.99 | 37.85 |
| Support Level | $0.86 | $0.61 |
| Resistance Level | $1.35 | $3.29 |
| Average True Range (ATR) | 0.20 | 0.68 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 11.21 | 2.58 |
Price Performance
Historical ComparisonAbout RUBI Rubico Inc.
Rubico Inc is an international provider of crude oil transportation services. The Company is engaged in the ownership and operation of a fleet of tanker vessels designed for enhanced fuel efficiency and reduced greenhouse gas emissions, incorporating environmentally friendly technologies.
About DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.